Evotec looks to move past share scandal with new CEO

24 April 2024

German drug discovery company Evotec (EVT: Xetra) has appointed Christian Wojczewski as chief executive, with the unanimous support of the board.

The incoming CEO will replace Mario Polywka, who has led Evotec on an interim basis since the start of the year, following the sudden departure of long-time chief Werner Lanthaler amid allegations of share trading impropriety.

Dr Lanthaler was accused of failing to report stock dealings on time, with the company stating it had reported the transactions to the market as soon as it found out.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK